MRMD (MariMed) 3-Year RORE % : -12.62% (As of Mar. 2026)


What is MariMed 3-Year RORE %?

MariMed MRMD +4.12% 3-Year RORE % is -12.62 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 937 Drug Manufacturers companies, MariMed ranks worse than 62.65% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. MariMed's 3-Year RORE % for the quarter that ended in Mar. 2026 was -12.62%.

The industry rank for MariMed's 3-Year RORE % or its related term are showing as below:

MRMD's 3-Year RORE % is ranked worse than
62.65% of 937 companies
in the Drug Manufacturers industry
Industry Median: 3.09 vs MRMD: -12.62

MariMed  (OTCPK:MRMD) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


MariMed 3-Year RORE % Related Terms


MariMed 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for MariMed's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed 3-Year RORE % Chart

MariMed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -111.68 55.17 -650.00 183.33 -15.79

MariMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.00 81.82 46.67 -15.79 -12.62

MRMD vs RMTI, CPHI, TXMD: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where MariMed's 3-Year RORE % falls into.



MariMed 3-Year RORE % Calculation

MariMed's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.03--0.043 )/( -0.103-0 )
=0.013/-0.103
=-12.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -12.62 mean?
MariMed (MRMD) has a 3-Year RORE % of -12.62 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #587 out of 937 companies in the Drug Manufacturers industry, placing it in the top 62.6%.
Is MariMed's 3-Year RORE % too high?
MariMed's current 3-Year RORE % is -12.62. Based on the distribution chart, MariMed ranks #587 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does MariMed's 3-Year RORE % compare to RMTI and CPHI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #587 out of 937 companies for 3-Year RORE %. This places MariMed in the lower half of its industry. The industry median 3-Year RORE % is 3.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current 3-Year RORE % is -12.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 57.4% below its estimated fair value. The current 3-Year RORE % is -12.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For MariMed (MRMD), the current 3-Year RORE % is -12.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MariMed Business Description

Other Exchanges MRMD:Canada
Address 10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.